Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note released on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently issued reports on the company. Barclays dropped their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Monday, December 23rd. Mizuho dropped their price objective on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. HC Wainwright reaffirmed a “neutral” rating and set a $6.60 target price on shares of Revance Therapeutics in a report on Friday, November 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Nine equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Stock Up 1.2 %

Shares of Revance Therapeutics stock opened at $3.29 on Monday. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.56. The company has a market cap of $343.44 million, a price-to-earnings ratio of -1.70 and a beta of 0.86. The company’s 50 day moving average is $3.61 and its 200 day moving average is $4.54.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $67.73 million. Sell-side analysts expect that Revance Therapeutics will post -1.57 EPS for the current fiscal year.

Institutional Trading of Revance Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. FNY Investment Advisers LLC boosted its holdings in Revance Therapeutics by 160.4% in the 4th quarter. FNY Investment Advisers LLC now owns 477,823 shares of the biopharmaceutical company’s stock worth $1,452,000 after buying an additional 294,323 shares during the period. Exome Asset Management LLC bought a new position in shares of Revance Therapeutics in the third quarter worth about $1,804,000. Oddo BHF Asset Management Sas purchased a new stake in shares of Revance Therapeutics during the third quarter worth about $3,763,000. Virtu Financial LLC bought a new stake in Revance Therapeutics during the 3rd quarter valued at approximately $120,000. Finally, Wellington Management Group LLP purchased a new position in Revance Therapeutics in the 3rd quarter worth approximately $2,315,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.